NCT02465060: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: BRCA+, EGFR, HER2+, MET, ALK, ROS, RAF, PI3K, FGFR, mTOR, TSC, PTEN, NF1/2, GNA, SMO, PTCH, KIT, Akt, RAS, CDK, Rb+, MLH, MSI-H, NTRK
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor, Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Any patient with a solid tumor is eligible; The trial matches patients to a specific experimental arm based on the mutations or molecular information of the tumor- see trial for full list of eligible mutations
Exclusions: 
https://clinicaltrials.gov/show/NCT02465060

Comments are closed.

Up ↑